| Chemical Properties | Back Directory | [density ]
1.251±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
13.608±0.70(predicted) | [color ]
White to yellow | [SMILES]
CC1=NC2=C(C(N1C3=CC=C(NC(CC4=CC(OC)=C(OC)C(OC)=C4)=O)C=C3)=O)C=CC=C2 |
| Hazard Information | Back Directory | [Uses]
icFSP1 is a potent ferroptosis suppressor protein-1 (FSP1) inhibitor. icFSP1 triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation, in synergism with GPX4 inhibition. icFSP1 induces ferroptosis. icFSP1 shows antitumor activity against melanoma.[1]. | [Biological Activity]
Selective and efficacious in vivo inhibitor of ferroptosis-suppressor-protein 1 (FSP1); ferroptosis inducer.
icFSP1 is a selective and efficacious in vivo inhibitor of ferroptosis-suppressor-protein 1 (FSP1). icFSP1 triggers subcellular relocalization of FSP1 from the membrane and initiate FSP1 reversible aggregation into liquid droplet-like structures before ferroptosis initiation. It synergizes with ferroptosis inducing agents to potentiate the ferroptotic cell death response. | [in vivo]
icFSP1 (50?mg/kg, i.p., twice daily) impairs tumour growth in a tumour-bearing (Gpx4 and Fsp1 double knockout B16F10 cells overexpressing hFSP1) mouse model[1].
| Animal Model: | Tumour-bearing (Gpx4 and Fsp1 double knockout B16F10 cells overexpressing hFSP1) mouse (C57BL/6J) model[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection (i.p.), twice daily | | Result: | Inhibited tumour growth and decreased tumour weight, without affecting body weight.
Increased the abundance of hFSP1 condensates and immunoreactivity to 4-hydroxynonenal (4-HNE).
|
| [References]
[1] Toshitaka Nakamura, et al. Phase separation of FSP1 promotes ferroptosis. Nature. 2023 Jul;619(7969):371-377. DOI:10.1038/s41586-023-06255-6 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|